Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Recent & Breaking News (OTCQX:RHHBY)

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

PR Newswire 3 days ago

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

PR Newswire 9 days ago

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024

Business Wire November 5, 2024

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer

Business Wire October 30, 2024

Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

Business Wire October 18, 2024

Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

PR Newswire October 18, 2024

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

Business Wire October 14, 2024

FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Business Wire October 10, 2024

Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public

PR Newswire October 8, 2024

Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis

Business Wire September 26, 2024

Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses

Business Wire September 19, 2024

FDA Approves Ocrevus Zunovo(TM) as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

Business Wire September 13, 2024

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Business Wire September 12, 2024

Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment

PR Newswire September 9, 2024

New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Business Wire July 18, 2024

Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

Business Wire July 17, 2024

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

Business Wire July 17, 2024

Remix Therapeutics(TM) Attains Near-Term Milestone from Roche Collaboration

PR Newswire July 10, 2024

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

Business Wire July 8, 2024

FDA Approves Genentech's Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

Business Wire July 5, 2024